1.0Spirahttps://spirainnovation.com/en/diezelhttps://spirainnovation.com/en/author/diezel/SpiraBiopsy - Spirarich600338<blockquote class="wp-embedded-content" data-secret="7OZj6AykSz"><a href="https://spirainnovation.com/en/produits/spirabiopsy/">SpiraBiopsy</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://spirainnovation.com/en/produits/spirabiopsy/embed/#?secret=7OZj6AykSz" width="600" height="338" title="“SpiraBiopsy” — Spira" data-secret="7OZj6AykSz" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script type="text/javascript">
/* <![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
/* ]]> */
</script>
https://spirainnovation.com/wp-content/uploads/2021/03/spira_biopsy-square.png10241024This patent-pending early cancer detection device tracks volatile organic compound (VOC) biomarkers in the breath of patients, indicating metabolic disturbances (such as various cancers) even before the first symptoms appear. Expected market launch: 2022